产品
编 号：F754146
分子式：C13H9N3O2S
分子量：271.29
分子式：C13H9N3O2S
分子量：271.29
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 26328-53-0
产品详情
生物活性：
Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma.
体内研究：
Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain.Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma.Amoscanate elicits massive ultrastructural damage in ependymal cells.Animal Model:Sprague-Dawley rats
Dosage:500 mg/kg
Administration:P.o.; 10 days
Result:Destructed ependyma and periventricular brain.
Animal Model:Sprague-Dawley rats
Dosage:250 and 500 mg/kg
Administration:P.o.; 28 days
Result:Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.
Animal Model:Sprague-Dawley rats
Dosage:25~500 mg/kg
Administration:P.o.; 20 days
Result:Elicited progressive necrosis of ependymal.
Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma.
体内研究：
Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain.Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma.Amoscanate elicits massive ultrastructural damage in ependymal cells.Animal Model:Sprague-Dawley rats
Dosage:500 mg/kg
Administration:P.o.; 10 days
Result:Destructed ependyma and periventricular brain.
Animal Model:Sprague-Dawley rats
Dosage:250 and 500 mg/kg
Administration:P.o.; 28 days
Result:Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.
Animal Model:Sprague-Dawley rats
Dosage:25~500 mg/kg
Administration:P.o.; 20 days
Result:Elicited progressive necrosis of ependymal.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备